Trial reportJournal of substance abuse treatment2008
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors.
Trial report in Journal of substance abuse treatment, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04521920 (Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs), which is not on this map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs: a Feasibility Study
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Oral substitution treatment of injecting opioid users for prevention of HIV infection.The Cochrane database of systematic reviews · 2011Pooled it
- Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.Harm reduction journal · 2024Trial
- Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.Harm reduction journal · 2022Trial
- Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.Journal of substance abuse treatment · 2022Trial
- Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.Addiction (Abingdon, England) · 2017Trial
- HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.Journal of acquired immune deficiency syndromes (1999) · 2014Trial
- Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers.Drug and alcohol dependence · 2013Trial
- Retention in methadone and buprenorphine treatment among African Americans.Journal of substance abuse treatment · 2013Trial
- Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.Journal of acquired immune deficiency syndromes (1999) · 2011Trial
- HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study.Journal of acquired immune deficiency syndromes (1999) · 2010Trial
- Concurrent Use of Extra-Medical Medication for Opioid Use Disorder Among Adults Prescribed Methadone or Buprenorphine: A Cohort Study of Urban Adults Who Have Injected Drugs.Drug and alcohol review · 2026Article
- Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination.The mental health clinician · 2025Article
- Perceived organizational support for the treatment of opioid use disorder and its association with primary care provider treatment willingness and medication prescribing.Journal of substance use and addiction treatment · 2025Article
- Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals.Addiction science & clinical practice · 2024Article
- Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.Harm reduction journal · 2023Article
- Sex and Female Empowerment (SAFE): Learning from health care providers, men and women to design a sexual health intervention for women with substance use disorders.Drug and alcohol dependence · 2023Article
- Peer recovery coaching for comprehensive HIV, hepatitis C, and opioid use disorder management: The CHORUS pilot study.Drug and alcohol dependence reports · 2023Article
- "I've been 95% safe": perspectives on HIV pre-exposure prophylaxis at a drug detoxification center: a qualitative study.AIDS care · 2023Article
- Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder.Open forum infectious diseases · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Methadone treatment reduces human immunodeficiency virus (HIV) risk, but the effects of primary-care-based buprenorphine/naloxone on HIV risk are unknown. The purpose of this study was to determine whether primary-care-based buprenorphine/naloxone was associated with decreased HIV risk behavior. We conducted a longitudinal analysis of 166 opioid-dependent persons (129 men and 37 women) receiving buprenorphine/naloxone treatment in a primary care clinic. We compared baseline and 12- and 24-week overall, drug-related, and sex-related HIV risk behaviors using the AIDS/HIV Risk Inventory (ARI). Buprenorphine/naloxone treatment was associated with significant reductions in overall and drug-related ARI scores from baseline to 12 and 24 weeks. Intravenous drug use in the past 3 months was endorsed by 37%, 12%, and 7% of patients at baseline and at 12 and 24 weeks, respectively (p< .001). Sex while you or your partner were "high" was endorsed by 64%, 13%, and 15% of patients at baseline and at 12 and 24 weeks, respectively (p< .001). Inconsistent condom use during sex with a steady partner was high at baseline and did not change over time. We conclude that primary-care-based buprenorphine/naloxone treatment is associated with decreased drug-related HIV risk, but additional efforts may be needed to address sex-related HIV risk when present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.